AndreaBozzo/ceres-open-data-index huggingface dataset:
Bone loss: Epidemiology of bone loss

Bone loss occurs when the cellular events of bone formation are quantitatively larger than bone formation. This manuscript discusses the measurement of bone loss, occurrence in the population, risk factors and consequences of bone loss. Recent developments in bone mass measurement and biomarkers have improved our ability to assess bone loss. This process is a normal concomitant of ageing. There are a number of other risk factors, including sex hormone deficiency, physical inactivity, calcium/vitamin D deficiency, inflammatory arthritis, corticosteroids, smoking and alcohol. The major consequence of bone loss in our ageing society is fracture.
Patent AT-E401340-T1: [Translated] METHOD FOR IMPROVING PROTEIN CONFORMITY USING REDUCING AGENTS

The present invention relates to a method for purifying a cysteine containing recombinantly expressed protein comprising at least 2, preferably 3 or 4 and even more preferably all of the following steps:  (a) sulphonation of a lysate from recombinant host cells or lysis of recombinant host cells in the presence of guanidinium chloride followed by a subsequent sulphonation of the cell lysate, (b) treatment with a zwitterionic detergent, preferably after removal of the cell debris, (c) purification of the sulphonated version of the recombinant protein or purification of the sulphonated version of the recombinant protein with subsequent removal of the zwitterionic detergent, with said purification being preferably chromatography, more preferably a Ni-IMAC chromatography with said recombinant protein being a His-tagged recombinant protein, (d) desulphonation of the sulphonated version of the recombinant protein, preferably with a molar excess of DTT, (e) storage in the presence of a molar excess of DTT.
Hamster oocyte membrane potential and ion permeability vary with preantral cumulus cell attachment and developmental stage

Background
          In vitro maturation of mammalian oocytes is an area of great interest due to its potential application in the treatment of infertility. The morphological and physiological changes that occur during oocyte development are poorly understood, and further studies are needed investigating the physiological changes associated with oocyte maturation. In this study we evaluated the membrane potential and the sodium/potassium permeability ratio of oocytes acutely isolated, and cumulus-oocyte complexes in metaphase II and preantral follicle stages.
        
        
          Results
          Intracellular electrical recordings revealed that cumulus-enclosed oocytes have a membrane potential significantly more negative at the preantral follicle stage than at metaphase II stage (-38.4 versus -19.7 mV, p < 0.0005). The membrane potential of the cumulus-free oocytes was not different between the preantral and metaphase II stages. The membrane potential of the cumulus cells forming preantral stage follicles was shown to be significantly different from that of the oocyte within the follicle (-28.6 versus -38.4 mV, p < 0.05). The sodium/potassium permeability measured in cumulus-enclosed oocytes at the preantral stage equaled a mean value of 0.33. The ratio was significantly lower when measured in oocytes denuded of cumulus cells or cumulus-enclosed metaphase II oocytes, 0.76, 0.79, 0.77 respectively (p < 0.001).
        
        
          Conclusions
          These data show a change in the membrane potential and Na+/K+ permeability ratio during ooycte development from the preantral stage oocyte to the metaphase II stage. We have also demonstrated a change in the preantral oocyte membrane potential when surrounding cumulus cells are removed; either due to membrane changes or loss of cumulus cells.
Treatment Episode Data Set: Admissions (TEDS-A-2009)

<p>The Treatment Episode Data Set -- Admissions (TEDS-A) is a national census data system of annual admissions to substance abuse treatment facilities. TEDS-A provides annual data on the number and characteristics of persons admitted to public and private substance abuse treatment programs that receive public funding. The unit of analysis is a treatment admission. TEDS consists of data reported to state substance abuse agencies by the treatment programs, which in turn report it to SAMHSA.<br />
A sister data system, called the Treatment Episode Data Set -- Discharges (TEDS-D), collects data on discharges from substance abuse treatment facilities. The first year of TEDS-A data is 1992, while the first year of TEDS-D is 2006.<br />
TEDS variables that are required to be reported are called the "Minimum Data Set (MDS)", while those that are optional are called the "Supplemental Data Set (SuDS)".<br />
Variables in the MDS include: information on service setting, number of prior treatments, primary source of referral, sex, race, ethnicity, education, employment status, substance(s) abused, route of administration, frequency of use, age at first use, and whether methadone was prescribed in treatment. Supplemental variables include: diagnosis codes, presence of psychiatric problems, living arrangements, source of income, health insurance, expected source of payment, pregnancy and veteran status, marital status, detailed not in labor force codes, detailed criminal justice referral codes, days waiting to enter treatment, and the number of arrests in the 30 days prior to admissions (starting in 2008) .<br />
Substances abused include alcohol, cocaine and crack, marijuana and hashish, heroin, nonprescription methadone, other opiates and synthetics, PCP, other hallucinogens, methamphetamine, other amphetamines, other stimulants, benzodiazepines, other non-benzodiazepine tranquilizers, barbiturates, other non-barbiturate sedatives or hypnotics, inhalants, over-the-counter medications, and other substances.<br />
Created variables include total number of substances reported, intravenous drug use (IDU), and flags for any mention of specific substances.This study has 1 Data Set.</p>
Treatment Episode Data Set  (TEDS): 2005-2015, National Admissions to Substance Abuse Treatment Services

This report presents national-level data from the Treatment Episode Data Set (TEDS) for admissions in 2015 and trend data from 2005 to 2015. It is a companion to the report Treatment Episode Data Set (TEDS): 2005-2015 State Admissions to Substance Abuse Treatment. These reports provide information on the demographic and substance abuse characteristics of admissions aged 12 and older to treatment for abuse of alcohol and/or drugs in facilities that report to individual state administrative data systems. Data include records for admissions during calendar years 2005 through 2015 that were received and processed through November 1, 2016.
Compound 526961: bis-(2-Nitrophenyl)acetic acid, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 2,2-bis(2-nitrophenyl)acetate. Molecular Formula: C15H12N2O6. Molecular Weight: 316.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525466: 4,4-Dimethyl-3-thiahexane

Chemical compound data from PubChem database. IUPAC Name: 2-ethylsulfanyl-2-methylbutane. Molecular Formula: C7H16S. Molecular Weight: 132.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Dextrose monohydrate and sodium chloride

Dextrose 5% and Sodium Chloride 0.225% is an intravenous solution that provides hydration, energy from dextrose, and essential electrolytes like sodium and chloride. It's used for fluid replacement in medical settings. Manufactured by ICU Medical Inc., available in 250mL, 500mL, and 1000mL plastic bags. This information was generated using AI and is provided for informational and research purposes only.
Compound 525439: 3,6-Dithianonane

Chemical compound data from PubChem database. IUPAC Name: 1-(2-ethylsulfanylethylsulfanyl)propane. Molecular Formula: C7H16S2. Molecular Weight: 164.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526168: Dimethyl 3-chlorophenyl phosphate

Chemical compound data from PubChem database. IUPAC Name: (3-chlorophenyl) dimethyl phosphate. Molecular Formula: C8H10ClO4P. Molecular Weight: 236.59. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401236-T1: [Translated] ANTI-THEFT DEVICE FOR BICYCLE HANDLEBAR

An anti-theft device for vehicles steered by means of a handlebar fixed to a fork (2, 3) accepting a steered wheel, comprising first means (12) of connection with the handlebar and second means (4, 5, 6) of connection with the fork, coupling means (7, 11, 18, 19, 20, 24) between the said first and second connection means, a two-position actuation device (21, 22, 23) locking any relative movement between the first and second connection means in the position of use of the vehicle and allowing free rotation between the said first and second connection means in the engaged position of the said anti-theft device, the actuation device comprising an interlocking mechanism (18, 21, 26), locked when the actuation device is in the anti-theft position and activated when the actuation device is in the position of use, independently of the relative positions of the handlebar and fork.
Patent AT-E400450-T1: [Translated] METHOD FOR PRODUCING A BOOK-LIKE VALUE DOCUMENT AND A BOOK-LIKE VALUE DOCUMENT

A method for producing a document of value involves formation of a laminate cover (25) with a surrounding sealed edge (24), by covering with at least one laminate layer, on at least one respective document side, a security insert (15) and a transponder unit (21). An independent claim is also included for a resultant document of value in the form of a booklet.
Compound 526288: 1,3-Dibromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,3-dibromodibenzofuran. Molecular Formula: C12H6Br2O. Molecular Weight: 325.98. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Cell adhesion and signaling on the fibronectin 1

Background
          The first type III repeat of fibronectin is known to be involved in fibronectin matrix assembly, and recombinant proteins from this type III repeat can inhibit cell proliferation, tumor metastasis and angiogenesis. We have analyzed the way rat aortic smooth muscle cells (RASMCs) interact with a recombinant protein encompassing a C-terminal portion of the first type III repeat of fibronectin (protein III1-C).
        
        
          Results
          Cells are able to adhere to and spread on III1-C coated on a dish. Both β1 integrins and cell surface heparan sulfate proteoglycans serve as receptors for III1-C. For example, cell attachment to III1-C is partially inhibited by agents that block β1 integrins or by heparin. Complete inhibition of cell attachment is seen only when integrin blocking agents are combined with heparin. Affinity chromatography revealed the binding of proteins that likely represent the integrin β1 and α5 submits to a III1-C column. Cell adhesion to III1-C results in robust ERK1/2 activation that is blocked by integrin-blocking agents. In addition, cell adhesion to III1-C and ERK1/2 activation by III1-C are both inhibited by heparan sulfate but not by chondroitin sulfate. Moreover, heparitinase treatment, but not chondroitinase treatment of RASMCs results in reduced cell adhesion and ERK1/2 activation. Affinity chromatography experiments demonstrated that 35SO4-labeled cell surface heparan sulfate proteoglycans bound specifically to III1-C.
        
        
          Conclusions
          The results suggest that the 1st type III repeat of fibronectin contains a previously unrecognized cell adhesion domain that stimulates robust ERK1/2 activation in RASMCs. Cells interact with this domain through cell surface heparan sulfate proteoglycans and integrins, and both classes of receptors are required for optimal cell adhesion and ERK1/2 activation.
Investigation ofKITgene mutations in women with 46,XX spontaneous premature ovarian failure

Spontaneous premature ovarian failure presents most commonly with secondary amenorrhea. Young women with the disorder are infertile and experience the symptoms and sequelae of estrogen deficiency. The mechanisms that give rise to spontaneous premature ovarian failure are largely unknown, but many reports suggest a genetic mechanism in some cases. The small family size associated with infertility makes genetic linkage analysis studies extremely difficult. Another approach that has proven successful has been to examine candidate genes based on known genetic phenotypes in other species. Studies in mice have demonstrated that c-kit, a transmembrane tyrosine kinase receptor, plays a critical role in gametogenesis. Here we test the hypothesis that humanKITmutations might be a cause of spontaneous premature ovarian failure.
Managed Care Individual Provider Network Data: March 31, 2013

The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans. This dataset reflects individual provider data. Provider Network Data System information is self-reported. For more information, check out: http://www.health.ny.gov/health_care/managed_care/.
U.S. State and Territorial Public Mask Mandates From April 10, 2020 through August 15, 2021 by County by Day

State and territorial executive orders, administrative orders, resolutions, and proclamations are collected from government websites and cataloged and coded using Microsoft Excel by one coder with one or more additional coders conducting quality assurance.

Data were collected to determine when members of the public in states and territories were subject to state and territorial executive orders, administrative orders, resolutions, and proclamations for COVID-19 that require them to wear masks in public. “Members of the public” are defined as individuals operating in a personal capacity. “In public” is defined to mean either (1) anywhere outside the home or (2) both in retail businesses and in restaurants/food establishments. Data consists exclusively of state and territorial orders, many of which apply to specific counties within their respective state or territory; therefore, data is broken down to the county level. 

These data are derived from publicly available state and territorial executive orders, administrative orders, resolutions, and proclamations (“orders”) for COVID-19 that expressly require individuals to wear masks in public found by the CDC, COVID-19 Community Intervention & Critical Populations Task Force, Monitoring & Evaluation Team, Mitigation Policy Analysis Unit, Center for State, Tribal, Local, and Territorial Support, Public Health Law Program, and Max Gakh, Assistant Professor, School of Public Health, University of Nevada, Las Vegas from April 10, 2020 through August 15, 2021.  These data will be updated as new orders are collected. Any orders not available through publicly accessible websites are not included in these data. Only official copies of the documents or, where official copies were unavailable, official press releases from government websites describing requirements were coded; news media reports on restrictions were excluded. Recommendations not included in an order are not included in these data. Effective and expiration dates were coded using only the dates provided; no distinction was made based on the specific time of the day the order became effective or expired. These data do not include data on counties that have opted out of their state mask mandate pursuant to state law. These data do not necessarily represent an official position of the Centers for Disease Control and Prevention.
Patent AT-E401055-T1: [Translated] METHOD FOR PRODUCING DISPERSIONS FOR FORMULATION OF LOWLY OR POORLY SOLUBLE ACTIVE INGREDIENTS

The invention provides a dispersion having an oily phase, an aqueous phase, in the form of an oil-in-water emulsion or a water-in-oil emulsion, and at least one active ingredient that is only slightly or with difficulty soluble in the oily phase and the aqueous phase. The dispersion is free from toxicologically dangerous organic solvents. The dispersion contains the active ingredient dissolved in a quantity that is greater than the quantity which results additively from its maximum solubility in the oily and the aqueous phase of the emulsion prior to forming the emulsion.
Golimumab

Simponi (golimumab) is a prescription medication manufactured by Janssen Biotech, Inc., used as a tumor necrosis factor (TNF) blocker to treat inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It comes as a subcutaneous injection in prefilled syringes containing 100 mg/mL solution. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E400801-T1: [Translated] DEVICE FOR DETECTING OR GENERATING OPTICAL SIGNALS

The system produces a reference light beam, which is frequency-shifted, modulated, time-shifted or phase-shifted compared to the optical signal to be determined. At least one wave-dependent facility (14) is provided, with which the optical beam to be determined and the reference light beams are aligned in such a manner, that they can be applied for interference. At least one detector (40) is arranged together with a demodulator (50) or other optical elements, so that a temporal or spatial modulation of the intensity related to the whole or part of the detected radiation cross-section can be measured.
Compound 528322: Pyrazine, 3-methylthio-2-octyl

Chemical compound data from PubChem database. IUPAC Name: 2-methylsulfanyl-3-octylpyrazine. Molecular Formula: C13H22N2S. Molecular Weight: 238.39. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530722: 2,6-Difluorobenzoic acid, 3-methylbut-2-enyl ester

Chemical compound data from PubChem database. IUPAC Name: 3-methylbut-2-enyl 2,6-difluorobenzoate. Molecular Formula: C12H12F2O2. Molecular Weight: 226.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Hospital Inpatient Discharges (SPARCS De-Identified): 2014

The Statewide Planning and Research Cooperative System (SPARCS) Inpatient De-identified File contains discharge level detail on patient characteristics, diagnoses, treatments, services, and charges.  This data file contains basic record level detail for the discharge.  The de-identified data file does not contain data that is protected health information (PHI) under HIPAA.  The health information is not individually identifiable; all data elements considered identifiable have been redacted.  For example, the direct identifiers regarding a date have the day and month portion of the date removed.
Managed Care Institutional Provider Network Data: June 30, 2013

The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans. This dataset reflects institutional provider data. Provider Network Data System information is self reported. For more information, go to http://www.health.ny.gov/health_care/managed_care/.
Annual Report to Congress on State Child Welfare Expenditures reported on the CFS-101 (2013)

This report to Congress provides national totals of planned spending by service category for the Stephanie Tubbs Jones Child Welfare Services program and planned and actual spending by service category for the Promoting Safe and Stable Families program.

Table of Contents

2013 Annual Report to Congress on State Child Welfare Expenditures Reported on the CFS-101 (PDF)
*Attachment A: State CFS-101s
Attachment B: CFS-101s Forms and Instructions
Attachment C: Stephanie Tubbs Jones Child Welfare Services: 2013 Planned Use of Funding by State and Service Category
Attachment D: Promoting Safe and Stable Families Program: 2013 Planned Use of Funding by State and Service Category
Attachment E: Promoting Safe and Stable Families: 2010 State Expenditures by State and Service Category

For questions on Attachments A: please contact, Catherine Heath

Metadata-only record linking to the original dataset. Open original dataset below.
Diligent Recruitment — Regional Resource Navigators

This Child Welfare Information Gateway Podcast is available on Apple Podcasts
  
  

, GooglePlay
  
  

, Spotify
  
  

, Stitcher
  
  

, SoundCloud
  
  

, and the Child Welfare Information Gateway
  
  

 website. Subscribe to receive new episodes as they are released.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 528136: 5-Isobutyl-3-methyl-2-(methylthio)pyrazine

Chemical compound data from PubChem database. IUPAC Name: 3-methyl-5-(2-methylpropyl)-2-methylsulfanylpyrazine. Molecular Formula: C10H16N2S. Molecular Weight: 196.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.